NasdaqCM:SAVAPharmaceuticals
What Does Cassava Sciences (SAVA) CEO’s Insider Buy Reveal About Its Post-Alzheimer’s Strategy?
Earlier this month, Cassava Sciences President and CEO Richard Barry made a significant personal investment by acquiring 237,941 shares valued at US$534,743 following the discontinuation of the company’s Alzheimer’s drug program due to disappointing clinical trial results.
This marked Barry’s first insider purchase in over a year and is being interpreted as a sign of confidence in Cassava’s remaining pipeline and future direction, as the company focuses on new opportunities including a...